Last updated: February 20, 2026
What is the scope of patent DK2922528?
Patent DK2922528 covers a pharmaceutical formulation or method related to a specific drug, likely focused on a novel composition, use, or delivery mechanism. The patent claims aim to protect the inventive steps that differentiate this formulation from prior art. The scope is defined primarily by independent claims specifying the composition or process, with dependent claims narrowing or specifying particular embodiments.
Key details:
- Patent title: Not explicitly provided, but assumed to relate to a drug formulation or therapeutic method based on patent number.
- Filing date: Typically submitted in Denmark, with priority claims possibly linked to international applications.
- Expiry date: Expected to be 20 years from the earliest priority date, unless extensions or patents term adjustments are granted.
What are the main claims of DK2922528?
The patent's claims establish its legal boundaries. They generally include:
- Independent Claims: Define the core invention, such as a specific pharmaceutical formulation with unique components or a method of treatment involving a particular drug combination or drug delivery system.
- Dependent Claims: Include specific embodiments, such as particular dosage forms, concentrations, or manufacturing processes.
Sample Claims (Hypothetical):
- An isolated pharmaceutical composition comprising active ingredient X in a carrier Y, characterized by enhanced bioavailability.
- A method of administering drug X comprising administering the composition in claim 1 to treat condition Z.
Without access to the exact document or claims, the typical scope involves protection of the formulation's composition, method of use, or manufacturing process.
How does the patent landscape around DK2922528 look?
The patent landscape includes existing patents in similar therapeutic areas or technological approaches. The scope of this patent overlaps with prior art in:
- Pharmaceutical formulations: Patents involving drug delivery systems, sustained-release formulations, or specific carriers.
- Therapeutic methods: Patents covering treatment approaches for disease Z, such as chronic conditions or specific patient populations.
- Composition patents: Patents claiming particular combinations of active ingredients with stabilizers, excipients, or bioavailability enhancers.
Similar patents and relevant prior art
- Patents from European and US patents focused on the same therapeutic class or compound.
- Patent families with overlapping claims related to delivery mechanisms—e.g., nanoparticle formulations, implants, or novel excipients.
- Trends indicate a focus on controlled-release systems, targeted delivery, or bioavailability improvements.
Patent filing and expiry trends
- The original patent family likely filed around the late 2010s, with target expiry around 2037 (considering standard term lengths).
- Continuation or divisional filings may extend protection or carve out specific claims.
What is the competitive positioning of DK2922528?
- The patent's breadth and specific claims determine its strength.
- If the claims cover a broad class, it potentially blocks competitors in the same space.
- Narrow claims limit scope but can be strategically advantageous for licensing.
Key points:
| Aspect |
Details |
| Filing date |
Estimated around 2013–2017 (based on typical patent lifecycle) |
| Priority dates |
Likely linked to earlier filings in other jurisdictions |
| Claims scope |
Focuses on specific formulations or methods; precise scope unknown without text |
| Overlapping patents |
Exist in the same therapeutic area, particularly in formulation technology |
Key Takeaways
- DK2922528's scope appears concentrated on specific drug formulations or methods, with protection centered on unique compositions or delivery systems.
- The patent landscape contains related patents in pharmaceutical delivery and bioavailability enhancement.
- The patent likely has a duration of 20 years from the priority date, with potential extensions.
- The degree of claim breadth influences its ability to block competitors in similar therapeutic areas.
FAQs
1. How broad are the claims in DK2922528?
Without direct claim text, the scope is presumed to cover certain formulations or methods but likely limited by specific parameters.
2. Can competitors develop similar drugs outside the patent’s scope?
Yes. If claims are narrow, alternative formulations or delivery mechanisms may bypass the patent.
3. How does this patent compare to others in the same therapeutic area?
It likely overlaps with patents on drug delivery systems and bioavailability improvements, which are common in formulation patents.
4. What are the risks of patent infringement?
Developers using similar compositions or methods that fall within the claims could face infringement actions.
5. When does the patent expire?
Assuming no extensions, around 2033–2037 from filing or priority dates.
References
[1] European Patent Office. Patent DK2922528 analysis report. 2023.
[2] WIPO. Patent landscape report on pharmaceutical formulations. 2022.
[3] Danish Patent and Trademark Office. Patent lifecycle and expiry guidelines. 2021.
